These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 35680806)
1. [Correlation between Serum miR-34a Level and Thrombocytopenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma]. Zhang HL; Uticul A; Xu XW; Shi YW Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):784-789. PubMed ID: 35680806 [TBL] [Abstract][Full Text] [Related]
2. Serum miR-146a level is a potential biomarker in predicting the outcome of diffuse large B-cell lymphoma. Huang X; Gui A; Zhou Y; Xia Z; Liu W; Zuo J; Yang L; Zhang Q Asia Pac J Clin Oncol; 2023 Oct; 19(5):e283-e290. PubMed ID: 36540006 [TBL] [Abstract][Full Text] [Related]
3. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma. Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484 [TBL] [Abstract][Full Text] [Related]
4. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index. Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of hsa-miR-548d-3p and overexpression of HOXA9 in diffuse large B-cell lymphoma patients and the risk of R-CHOP chemotherapy resistance and disease progression. Ting CY; Tan SY; Gan GG; Zain SM; Pung YF; Ong DB; Bee PC Int J Lab Hematol; 2022 Oct; 44(5):907-917. PubMed ID: 35830966 [TBL] [Abstract][Full Text] [Related]
6. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone. Wu PY; Zhang XD; Zhu J; Guo XY; Wang JF Hum Pathol; 2014 Aug; 45(8):1664-73. PubMed ID: 24931464 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. Due H; Schönherz AA; Ryø L; Primo MN; Jespersen DS; Thomsen EA; Roug AS; Xiao M; Tan X; Pang Y; Young KH; Bøgsted M; Mikkelsen JG; Dybkær K Blood Adv; 2019 Apr; 3(7):1185-1196. PubMed ID: 30967394 [TBL] [Abstract][Full Text] [Related]
8. Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Song G; Gu L; Li J; Tang Z; Liu H; Chen B; Sun X; He B; Pan Y; Wang S; Cho WC Ann Hematol; 2014 Oct; 93(10):1735-43. PubMed ID: 24858372 [TBL] [Abstract][Full Text] [Related]
9. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study. Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700 [TBL] [Abstract][Full Text] [Related]
10. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062 [TBL] [Abstract][Full Text] [Related]
11. miR-21 expression predicts prognosis in diffuse large B-cell lymphoma. Li J; Fu R; Yang L; Tu W Int J Clin Exp Pathol; 2015; 8(11):15019-24. PubMed ID: 26823838 [TBL] [Abstract][Full Text] [Related]
12. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era. Nakayama S; Matsuda M; Adachi T; Sueda S; Ohashi Y; Awaji S; Hashimoto S; Matsumura I Platelets; 2019; 30(5):637-645. PubMed ID: 30047815 [TBL] [Abstract][Full Text] [Related]
13. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461 [TBL] [Abstract][Full Text] [Related]
14. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies. Purdum A; Tieu R; Reddy SR; Broder MS Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561 [TBL] [Abstract][Full Text] [Related]
15. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy. Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188 [TBL] [Abstract][Full Text] [Related]
17. [Aidi Injection-Asisted R-CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma]. Lu GQ; Zhou XH; Chen H; Tan JP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):733-7. PubMed ID: 27342500 [TBL] [Abstract][Full Text] [Related]
18. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ; Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632 [TBL] [Abstract][Full Text] [Related]
19. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893 [TBL] [Abstract][Full Text] [Related]
20. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Wöhrer S; Püspök A; Drach J; Hejna M; Chott A; Raderer M Ann Oncol; 2004 Jul; 15(7):1086-90. PubMed ID: 15205203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]